<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6588">
  <stage>Registered</stage>
  <submitdate>20/05/2016</submitdate>
  <approvaldate>20/05/2016</approvaldate>
  <nctid>NCT02781584</nctid>
  <trial_identification>
    <studytitle>Safety, Tolerability, and Efficacy of Selonsertib, GS-0976, and GS-9674 in Adults With Nonalcoholic Steatohepatitis (NASH)</studytitle>
    <scientifictitle>A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>GS-US-384-3914</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Nonalcoholic Steatohepatitis (NASH)</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Metabolic disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and Nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - SEL
Treatment: drugs - GS-0976
Treatment: drugs - GS-9674

Experimental: SEL (Cohort 1) - SEL (1 x 18 mg tablet) for 12 weeks

Experimental: GS-0976 (Cohort 2) - GS-0976 (2 x 10 mg capsules) for 12 weeks
Enrollment into Cohort 2 will begin upon completion of enrollment for Cohort 1.

Experimental: GS-9674 (Cohort 3) - GS-9674 (3 x 10 mg tablets) for 12 weeks
Enrollment into Cohort 3 will begin upon completion of enrollment for Cohort 2.

Experimental: SEL+GS-9674 (Cohort 4) - SEL (1 x 18 mg tablet) + GS-9674 (1 x 30 mg tablet) for 12 weeks
Enrollment into Cohort 4 will begin upon completion of enrollment for Cohort 3.

Experimental: SEL+GS-0976 (Cohort 5) - SEL (1 x 18 mg tablet) + GS-0976 (1 x 20 mg tablet) for 12 weeks
Enrollment into Cohort 5 will begin upon completion of enrollment for Cohort 4.

Experimental: GS-0976+GS-9674 (Cohort 6) - GS-0976 (1 x 20 mg tablet) + GS-9674 (1 x 30 mg tablet) for 12 weeks
Enrollment into Cohort 6 will begin upon completion of enrollment for Cohort 5.

Experimental: GS-0976 Cirrhotic (Cohort 7) - GS-0976 (1 x 20 mg tablet) for 12 weeks (participants with Child-Pugh-Turcotte Class A (CPT A) cirrhosis)
Enrollment into Cohorts 7 and 8 will be randomized in parallel.

Experimental: GS-9674 Cirrhotic (Cohort 8) - GS-9674 (1 x 30 mg tablet) for 12 weeks (participants with CPT A cirrhosis)
Enrollment into Cohorts 7 and 8 will be randomized in parallel.


Treatment: drugs: SEL
Administered orally once daily

Treatment: drugs: GS-0976
Administered orally once daily

Treatment: drugs: GS-9674
Administered orally once daily

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of Treatment-Emergent Adverse Events</outcome>
      <timepoint>Up to 12 weeks plus 30 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of Treatment-Emergent Serious Adverse Events</outcome>
      <timepoint>Up to 12 weeks plus 30 days</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of Treatment-Emergent Laboratory Abnormalities</outcome>
      <timepoint>Up to 12 weeks plus 30 days</timepoint>
    </primaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Males and females between 18-75 years of age; inclusive based on the date of the
             screening visit

          -  Willing and able to provide informed consent prior to any study specific procedures
             being performed

          -  Meets the following conditions (Cohorts 1-6):

               -  Clinical diagnosis of non-alcoholic fatty liver disease, screening FibroTest® &lt;
                  0.75, unless a historical liver biopsy within 12 months of screening does not
                  reveal cirrhosis, screening magnetic resonance imaging - proton density fat
                  fraction (MRI-PDFF) with = 10% steatosis, and screening magnetic resonance
                  elastography (MRE) with liver stiffness = 2.88 kPa OR

               -  A historical liver biopsy within 12 months of screening consistent with NASH
                  (defined as the presence of steatosis, inflammation, and ballooning) with stage
                  2-3 fibrosis according to the NASH Clinical Research Network (CRN) classification
                  (or equivalent) and no documented weight loss &gt; 5% between the date of the liver
                  biopsy and screening

          -  For Cohorts 7 and 8, subjects must have a clinical diagnosis of NAFLD and have at
             least one of the following criteria (a-d): a) Screening MRE with liver stiffness =
             4.67 kPa; b) A historical FibroScan = 14 kPa within 6 months of Screening; C)
             Screening FibroTest® = 0.75; d) A historical liver biopsy consistent with stage 4
             fibrosis according to the NASH CRN classification (or equivalent)

        Key</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnant or lactating females

          -  Other causes of liver disease including autoimmune, viral, and alcoholic liver disease

          -  Any history of decompensated liver disease, including ascites, hepatic encephalopathy
             or variceal bleeding

          -  For Cohorts 7 and 8, Child-Pugh-Turcotte (CPT) score &gt; 6

          -  History of liver transplantation

        Note: Other protocol defined Inclusion/Exclusion criteria may apply.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>13/07/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>110</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/05/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Gilead Sciences</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary objective of this study is to evaluate the safety and tolerability of selonsertib
      (SEL; formerly GS-4997), GS-0976, and GS-9674 in adults with nonalcoholic steatohepatitis
      (NASH).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02781584</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Gilead Study Director</name>
      <address>Gilead Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Gilead Study Team</name>
      <address />
      <phone />
      <fax />
      <email>384-3914alerts@gilead.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>